Janux Therapeutics (JANX) Operating Leases (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Operating Leases data on file, last reported at $19.1 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $19.1 million, down 8.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.1 million (down 8.18% YoY), and the FY2025 annual result was $19.7 million, down 7.19% from the prior year.
• Operating Leases fell to $19.1 million in Q1 2026 per JANX's latest filing, from $19.7 million in the prior quarter.
• Over five years, Operating Leases peaked at $24.5 million in Q4 2022 and troughed at $19.1 million in Q1 2026.
• A 5-year average of $22.2 million and a median of $22.4 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2025: Operating Leases soared 104647.83% in 2022, then decreased 8.44% in 2025.
• A 5-year view of Operating Leases shows it stood at $24.5 million in 2022, then dropped by 6.18% to $23.0 million in 2023, then dropped by 7.6% to $21.3 million in 2024, then slipped by 7.19% to $19.7 million in 2025, then retreated by 3.28% to $19.1 million in 2026.
• Business Quant data shows JANX's Operating Leases at $19.1 million in Q1 2026, $19.7 million in Q4 2025, and $20.4 million in Q3 2025.